Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.61 |
| ▸ | CA12 | O43570 | 14/20 | 0.61 |
| ▸ | CA9 | Q16790 | 14/20 | 0.61 |
| ▸ | KIF11 | P52732 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 14/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3637984 | 0.94 | CA2 (0.55) | CA2CA12CA9KIF11CA1 | |
| SCHEMBL18118194 | 0.84 | CA2 (0.67) | CA2CA12CA9KIF11CA1 | |
| SCHEMBL4490768 | 0.82 | HSD11B1 (0.49) | KIF11HSD11B1 | |
| SCHEMBL18802754 | 0.78 | KIF11 (0.44) | KIF11MEN1KMT2AHSD11B1 | |
| SCHEMBL547767 | 0.78 | KIF11 (0.44) | KIF11MEN1KMT2AHSD11B1 | |
| SCHEMBL2906790 | 0.77 | HSD11B1 (0.65) | HSD11B1 | |
| SCHEMBL283836 | 0.77 | CA2 (0.70) | CA2CA12CA9KIF11CA1 | |
| SCHEMBL28345242 | 0.77 | CA2 (0.59) | CA2CA12CA9KIF11CA1 | |
| SCHEMBL25516405 | 0.77 | KMT2A (0.57) | CA2CA12CA9KIF11CA1 | |
| SCHEMBL20680957 | 0.75 | KIF11 (0.59) | CA2CA12CA9KIF11CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | US | claimed |
| EP-1893562-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | Merck Frosst Canada Ltd. (CA) | 2008-03-05 | — | — | EP | claimed |
| WO-2006133559-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | MERCK FROSST CANADA LTD. (CA) | 2006-12-21 | — | — | WO | claimed |
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | US | disclosed |
| EP-1893562-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | Merck Frosst Canada Ltd. (CA) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006133559-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | MERCK FROSST CANADA LTD. (CA) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MAOB, MAOA, XDH | CA2 2379/4885CA12 4410/4885CA9 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.